Understand · Treat · Recover
Treatment After Progression
Progression calls for a new assessment of the cancer, prior treatment, remaining toxicities and the person’s goals.
For patients, families and caregivers worldwide. Approvals, access and care pathways vary by country. Evidence checked 21 October 2026.
This information is provided for general educational purposes and does not replace individualized medical advice. Diagnosis and treatment decisions should be made with a qualified healthcare team.
Chapter 16 of 20
Confirm what has changed
Review scans alongside symptoms and the timing of treatment. A single tumour-marker rise is not always progression. Consider whether biopsy is needed to confirm a new lesion or reassess HER2 and other actionable findings. Worsening function can arise from infection, dehydration, anemia, obstruction or toxicity as well as cancer; reversible problems should be treated.
Common second-line choices
Paclitaxel plus ramucirumab is a standard option for suitable patients. Residual neuropathy, bleeding risk, uncontrolled blood pressure and recent surgery can change that choice. Irinotecan-based treatment, including FOLFIRI in appropriate practice settings, or a single-agent option may be considered. Prior drugs, response duration, blood counts and organ function matter more than simply moving to a numbered line.
HER2-positive disease after trastuzumab
T-DXd is an important option when eligibility is confirmed. DESTINY-Gastric04 required HER2-positive disease on a post-progression biopsy and demonstrated superior overall survival versus ramucirumab–paclitaxel in the second-line study population. Reassessment matters because HER2 can be lost. Lung toxicity risk, monitoring and the local label must be considered before treatment.
Later-line treatment
Trifluridine/tipiracil is an oral later-line treatment supported in previously treated metastatic gastric/GEJ adenocarcinoma, including after appropriate fluoropyrimidine, platinum, taxane or irinotecan and HER2 therapy when relevant. It can cause substantial neutropenia and anemia and needs a precise dosing calendar and monitoring. TAGS showed a survival benefit compared with placebo plus supportive care; the benefit is meaningful but not a promise of tumour shrinkage for everyone.
Immunotherapy and trials
Selected immunotherapy can be appropriate for MSI-high/dMMR disease or another valid jurisdiction-specific indication, especially if not previously given. Continuing or switching PD-1 drugs after progression is not automatically effective. PD-L1 positivity alone does not recreate withdrawn later-line indications. Rare actionable changes and clinical trials may offer options, but experimental treatments should be identified clearly.
Adenocarcinoma is not squamous carcinoma
The gastric/GEJ evidence for trifluridine/tipiracil and HER2-directed treatment should not be assumed effective for esophageal squamous cell carcinoma. That disease has separate evidence and approved options. At every line, discuss whether the expected benefit outweighs clinic time, toxicity and cost. Choosing symptom-focused care can be an active, informed decision with continued medical support.
Key takeaways
Select the next treatment by biology, prior exposure and remaining fitness—not by habit.
Frequently asked questions
Is there treatment after first-line failure?
Often yes, depending on fitness, previous exposure and available options.
Should HER2 be retested?
It can be valuable after progression on trastuzumab, particularly when considering T-DXd.
Is trifluridine/tipiracil established for esophageal squamous cancer?
No. Its gastric/GEJ indication is for adenocarcinoma, and should not be extrapolated to squamous disease.
Can ramucirumab be used with major bleeding?
Bleeding risk requires careful assessment and may make it unsuitable.
Does changing one immunotherapy to another usually overcome resistance?
Not reliably; this is not a routine assumption after progression.
When is stopping anticancer treatment reasonable?
When likely harm exceeds benefit, functional decline limits safe treatment, or the patient chooses a comfort-focused plan.